2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab (Keytruda) in patients with advanced neuroendocrine tumors (NETs).
The results were not encouraging with only 4 of the 107 patients responding, Strosberg says. All of the responders were PD-L1-negative, concluding that this was not a predictive biomarker. This trial did not show any clear direction in terms of what type of NET will respond tp pembrolizumab treatment.
The data shows that single-agent PD-1/PD-L1 inhibitor is not active in this patient population. Combinations or other options should be looked at in the future, Strosberg concludes.